To review the latest information about levels of anti-tuberculosis (TB) drug resistance in the European Region of the World Health Organization (WHO) and time-trends in multidrug-resistant TB (resistance to isoniazid and rifampicin; MDR-TB) over the past fifteen years. We analysed data on drug resistance among new and previously treated TB cases reported from 1997 to 2012. Data are collected in surveys of representative samples of TB patients or from surveillance systems based on diagnostic drug susceptibility testing. A total of 15.7% (95% confidence limits (CI): 9.5-21.9) of new and 45.3% (95%CI: 39.2-51.5) of previously treated TB cases are estimated to have MDR-TB in the Region. Extensively drug-resistant TB (MDR-TB and resistance to fluoroquinolones and second-line injectables; XDR-TB) had been reported by 38 of the 53 countries of the region (72%). The proportion of MDR-TB cases with XDR-TB is 11.4% (95%CI: 8.6-14.2). Between 1997 and 2012, population rates of MDR-TB declined in Estonia, Latvia and Germany and increased in the United Kingdom, Sweden and Tomsk Oblasts of the Russian Federation. Surveillance of drug resistance has been strengthened in the WHO European Region, which has the highest proportions of MDR-TB and XDR-TB ever reported globally. More complete data are needed particularly from the Russian Federation.

中文翻译：

---

世卫组织欧洲区域的耐药结核病：监测数据分析。

回顾有关世界卫生组织欧洲区域（WHO）抗结核（TB）耐药水平和耐多药结核病（耐异烟肼和利福平; MDR-TB）的时间趋势的最新信息。过去的十五年 我们分析了1997年至2012年报告的新的和先前治疗的结核病患者中的耐药性数据。这些数据收集在结核病患者代表性样本的调查中或基于诊断性药物敏感性测试的监测系统中收集。据估计，该地区总共有15.7％（95％的可信度（CI）：9.5-21.9）和以前治疗过的TB病例的45.3％（95％CI：39.2-51.5）。广泛耐药结核病（耐多药结核病和对氟喹诺酮类药物和二线注射剂的耐药性；该地区53个国家中有38个报告了XDR-TB）（占72％）。耐多药结核病的耐多药结核病比例为11.4％（95％CI：8.6-14.2）。在1997年至2012年之间，爱沙尼亚，拉脱维亚和德国的耐多药结核病发病率下降，而英国，瑞典和俄罗斯联邦的托木斯克州则上升。世卫组织欧洲区域加强了对耐药性的监测，该区域是全球报告的耐多药结核病和广泛耐药结核病比例最高的地区。特别是俄罗斯联邦需要更完整的数据。世卫组织欧洲区域加强了对耐药性的监测，该区域是全球报告的耐多药结核病和广泛耐药结核病比例最高的地区。特别是俄罗斯联邦需要更完整的数据。世卫组织欧洲区域加强了对耐药性的监测，该区域是全球报告的耐多药结核病和广泛耐药结核病比例最高的地区。特别是需要俄罗斯联邦提供更完整的数据。